In 2010, Olympus bought Stryker's troubled OP-1 putty for $60 million, hoping to expand its market. Now, the Japanese maker of medical devices and cameras says it's selling the Lebanon, NH, plant where the putty is made at a bargain price--and if it can't make a deal it will close the facility.
Forget organic growth. In 2013, some of the biggest moves into new or expanded markets in the med tech world came through serious M&A activity. The top deals announced or closed in 2013 created...
With Smith & Nephew shoring up its sports medicine device offerings in a major acquisition, Stryker is now trying to do the same with its second acquisition in a week.
More M&A is key to Stryker's strategy to build higher 2014 sales through investments in innovation and globalization, and the Michigan device company now says it will snatch up a German surgical equipment maker for $172 million.
Stryker closed out 2013 with a healthy rise in net sales and earnings in the fourth quarter. Organic growth and acquisitions in China and elsewhere drove those gains, but acquisition costs and recall-related charges prevented those results from reaching higher levels for the year as a whole
Stryker announced that it will partner with Samsung unit NeuroLogica to sell a full-body portable computed tomography (CT) scanner. The two companies will market the device for use by surgeons in the fields of neurology, orthopedics and trauma.
Stryker is planning to trade $120 million for Patient Safety Technologies and its trackable surgical instruments, joining the ranks of medical device outfits looking to expand their hospital service offerings in a growing market.
One remaining member of Stryker's founding family remains active on the board, and she has just sold a massive amount of company shares.
Stryker ($SYK) is settling the first of hundreds of lawsuits alleging it sold defective metal hip implants that harmed patients. Expect the orthopedic device company to pursue this path more often in the coming months, considering the mounting costs it has faced in the matter.
Stryker wants Mako Surgical badly, so much so that it offered up to $1.7 billion for it, an 86% premium for the company's stock before news of the deal came out in September. With such a rich offer, how could Mako's shareholders say no? They didn't, and voted recently to approve the sale, which will close on Dec. 17.